# A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

> **NCT04933695** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 42 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sotorasib

## Key facts

- **NCT ID:** NCT04933695
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-28
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-05-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933695, "A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04933695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*